Mannatech Inc (MTEX) stock
MTEXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/3045% below fair value
$6.30−2.68 (-29.84%)
Close on Nov 13, 2026Market cap $12.16MP/E –Yield –
Mannatech EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Mannatech's EPS for the twelve months ending Sep 30, 2026 was -$0.31. For fiscal 2025 it was -$8.00, down 706.1% from the year before. The highest annual figure on record is $4.71 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.00 | -706.1% |
| FY2024 | Dec 31, 2024 | $1.32 | – |
| FY2023 | Dec 31, 2023 | -$1.20 | – |
| FY2022 | Dec 31, 2022 | -$2.35 | -149.9% |
| FY2021 | Dec 31, 2021 | $4.71 | +70.0% |
| FY2020 | Dec 31, 2020 | $2.77 | +105.2% |
| FY2019 | Dec 31, 2019 | $1.35 | – |
| FY2018 | Dec 31, 2018 | -$1.53 | – |
| FY2017 | Dec 31, 2017 | -$0.66 | – |
| FY2016 | Dec 31, 2016 | -$0.22 | -110.3% |
| FY2015 | Dec 31, 2015 | $2.14 | -10.8% |
| FY2014 | Dec 31, 2014 | $2.40 | +103.4% |
| FY2013 | Dec 31, 2013 | $1.18 | – |
| FY2012 | Dec 31, 2012 | -$0.52 | – |
| FY2011 | Dec 31, 2011 | -$7.80 | – |
| FY2010 | Dec 31, 2010 | -$4.01 | – |
| FY2009 | Dec 31, 2009 | -$6.56 | – |
| FY2008 | Dec 31, 2008 | -$4.80 | -292.0% |
| FY2007 | Dec 31, 2007 | $2.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.61 | +356.4% |
| Q2 FY2026 | Jun 30, 2026 | $0.53 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.49 | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.94 | -595.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.01 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.27 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.80 | -227.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.20 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.17 | -1800.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.33 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.63 | +96.9% |
| Q4 FY2023 | Dec 31, 2023 | -$0.94 | -254.1% |
| Q3 FY2023 | Sep 30, 2023 | $0.01 | -97.1% |
| Q2 FY2023 | Jun 30, 2023 | -$0.59 | -1083.3% |
| Q1 FY2023 | Mar 31, 2023 | $0.32 | -67.7% |
| Q3 FY2022 | Sep 30, 2022 | $0.61 | -41.3% |
| Q2 FY2022 | Jun 30, 2022 | $0.34 | 0.0% |
| Q1 FY2022 | Mar 31, 2022 | $0.06 | -92.1% |
| Q2 FY2021 | Jun 30, 2021 | $0.99 | +110.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.04 | -9.6% |
| Q4 FY2020 | Dec 31, 2020 | $0.34 | -60.9% |
| Q3 FY2020 | Sep 30, 2020 | $0.76 | – |
| Q2 FY2020 | Jun 30, 2020 | $0.47 | -42.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.15 | +310.7% |
| Q4 FY2019 | Dec 31, 2019 | $0.87 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.62 | – |
| Q2 FY2019 | Jun 30, 2019 | $0.81 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.28 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.66 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.69 | -238.0% |
| Q2 FY2018 | Jun 30, 2018 | -$0.14 | -121.5% |
| Q1 FY2018 | Mar 31, 2018 | -$0.10 | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.48 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.50 | +8.7% |
| Q2 FY2017 | Jun 30, 2017 | $0.65 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.46 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.49 | – |
| Q3 FY2016 | Sep 30, 2016 | $0.46 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?